| Business Summary | | OSI
Pharmaceuticals,
Inc.
is
a
biopharmaceutical
company
focused
on
the
discovery
and
development
of
gene-targeted,
small
molecule
drugs,
in
the
areas
of
cancer,
respiratory
diseases,
diabetes
and
cosmeceuticals.
Independently,
and
with
its
corporate
partners,
the
Company
has
built
a
pipeline
of
discovery
programs
and
drug
candidates
for
46
individual
gene
targets,
addressing
major,
unmet
clinical
needs
and
significant
commercial
opportunities.
The
Company
has
two
candidates
in
clinical
trials
and
nine
projects
with
candidates
in
late
stage
pre-clinical
development.
OSI-774,
the
Company's
small
molecule
anti-cancer
agent,
is
a
potent,
selective
and
orally
active
inhibitor
of
epidermal
growth
factor
receptor
(EGFR).
The
protein
product
of
the
EGFR
gene
is
a
receptor
tyrosine
kinase
(RTK)
that
is
over-expressed
in
approximately
30%
of
all
major
cancers.
OSI-774
is
an
oral,
once-a-day
small
molecule
drug
designed
to
specifically
block
the
activity
of
the
EGFR
protein. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | OSI
Pharmaceuticals,
Inc.
utilizes
a
platform
of
proprietary
technologies
in
order
to
discover
and
develop
novel,
small
molecule
compounds
for
the
treatment
of
major
human
diseases.
For
the
nine
months
ended
6/30/01,
revenues
decreased
12%
to
$19.6
million.
Net
loss
before
acct.
change
rose
43%
to
$6.4
million.
Revenues
reflect
the
conclusion
of
funded
collaborations.
Net
loss
also
reflects
the
absence
of
a
$3.7
million
gain
on
the
sale
of
the
diagnostics
business. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Colin Goddard, Ph.D., 41 Chairman,
CEO | $533K | $1.8M | Nicholas Bacopoulos, Ph.D., 51 Pres
and Head of R&D | -- | -- | Robert Van Nostrand, 43 CFO,
Treasurer, VP, Sec. | 199K | 1.7M | Arthur Bruskin, Ph.D., 45 Exec.
VP, Pharmaceutical Operations | 266K | 2.3M | Eric Collington, Ph.D., 55 VP
- Chemistry | -- | -- | Dollar
amounts are as of 30-Sep-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|